PL351767A1 - Heteroaryl amidines, methylamidines and guanidines as protease inhibitors - Google Patents

Heteroaryl amidines, methylamidines and guanidines as protease inhibitors

Info

Publication number
PL351767A1
PL351767A1 PL99351767A PL35176799A PL351767A1 PL 351767 A1 PL351767 A1 PL 351767A1 PL 99351767 A PL99351767 A PL 99351767A PL 35176799 A PL35176799 A PL 35176799A PL 351767 A1 PL351767 A1 PL 351767A1
Authority
PL
Poland
Prior art keywords
methylamidines
guanidines
protease inhibitors
amidines
heteroaryl
Prior art date
Application number
PL99351767A
Other languages
English (en)
Inventor
Carl R Illig
Nalin L Subasinghe
James B Hoffman
Kenneth J Wilson
M Jonathan Rudolph
Juan Jose Marugan
Original Assignee
Dimensional Pharmaceuticals 3
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dimensional Pharmaceuticals 3 filed Critical Dimensional Pharmaceuticals 3
Publication of PL351767A1 publication Critical patent/PL351767A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
PL99351767A 1999-02-09 1999-08-11 Heteroaryl amidines, methylamidines and guanidines as protease inhibitors PL351767A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24706299A 1999-02-09 1999-02-09
PCT/US1999/018065 WO2000047578A1 (fr) 1999-02-09 1999-08-11 Amidines, methylamidines et guanidines, heteroaryles, en tant qu'inhibiteurs de proteases

Publications (1)

Publication Number Publication Date
PL351767A1 true PL351767A1 (en) 2003-06-16

Family

ID=22933398

Family Applications (1)

Application Number Title Priority Date Filing Date
PL99351767A PL351767A1 (en) 1999-02-09 1999-08-11 Heteroaryl amidines, methylamidines and guanidines as protease inhibitors

Country Status (19)

Country Link
EP (1) EP1150979A1 (fr)
JP (1) JP2002536446A (fr)
KR (1) KR20010098982A (fr)
CN (1) CN1337961A (fr)
AU (1) AU5671799A (fr)
BG (1) BG105866A (fr)
BR (1) BR9917036A (fr)
CA (1) CA2362390A1 (fr)
CZ (1) CZ20012858A3 (fr)
EA (1) EA200100882A1 (fr)
HU (1) HUP0201475A2 (fr)
IL (1) IL144560A0 (fr)
MX (1) MXPA01008084A (fr)
NO (1) NO324887B1 (fr)
NZ (1) NZ513701A (fr)
PL (1) PL351767A1 (fr)
SK (1) SK11422001A3 (fr)
WO (1) WO2000047578A1 (fr)
ZA (1) ZA200106849B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1152759A2 (fr) * 1999-02-09 2001-11-14 3-Dimensional Pharmaceuticals, Inc. METHODES DE TRAITEMENT DE MALADIES ET PATHOLOGIES INDUITES PAR C1s, COMPOSES ET COMPOSITIONS PREPARES A CET EFFET
US7109354B2 (en) * 2002-05-28 2006-09-19 3-Dimensional Pharmaceuticals, Inc. Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
HUE025683T2 (hu) 2002-12-03 2016-04-28 Pharmacyclics Llc VIIA faktor inhibitor 2-(2-hidroxi-bifenil-3-il)-1H-benzoimidazol-5-karboxamidin-származékok
US7482376B2 (en) * 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
KR20070007759A (ko) * 2003-07-10 2007-01-16 아칠리온 파르마세우티칼스 인코포레이티드 바이러스 복제 억제제로서 유용한 치환된 아릴티오우레아유도체
EP1718342A4 (fr) 2004-02-12 2009-07-22 Molecular Insight Pharm Inc Complexes de technetium-bis(heteroaryl) et de rhenium-bis(heteroaryl) et methodes d'utilisation associees
AU2009303335B2 (en) * 2008-10-09 2016-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase
CN102482249B (zh) 2009-07-08 2016-06-08 德米拉(加拿大)公司 用于治疗皮肤病症或疾病状态的tofa类似物
WO2011137089A1 (fr) 2010-04-29 2011-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Activateurs de la pyruvate kinase humaine
ES2693107T3 (es) * 2011-01-25 2018-12-07 The Regents Of The University Of Michigan Inhibidores de Bcl-2/Bcl-xL para su uso en el tratamiento del cáncer
AR086744A1 (es) * 2011-06-28 2014-01-22 Nippon Soda Co Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria
EP2606726A1 (fr) * 2011-12-21 2013-06-26 Bayer CropScience AG Dérivés de trifluoroéthylsulfure substitués par du N-arylamidine en tant qu'acaricides et insecticides
TWI644899B (zh) 2013-02-04 2018-12-21 健生藥品公司 Ｆｌａｐ調節劑
EP3495359A1 (fr) * 2013-02-04 2019-06-12 Janssen Pharmaceutica NV Modulateurs à flap
JP7301042B2 (ja) * 2018-03-30 2023-06-30 住友化学株式会社 複素環化合物及びそれを含有する有害節足動物防除組成物
CN109020837A (zh) * 2018-07-27 2018-12-18 广东省石油与精细化工研究院 一种2-取代苯基-乙脒盐酸盐的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4220654A (en) * 1979-06-04 1980-09-02 Merck & Co., Inc. Cyclic imidazole cyanoguanidines
US4424367A (en) * 1982-08-19 1984-01-03 Norwich Eaton Pharmaceuticals, Inc. 5-(4-Aminophenyl)-2-thiophenecarboximidamide hydrochloride hemihydrate
JPS59139357A (ja) * 1983-01-28 1984-08-10 Torii Yakuhin Kk アミジン誘導体
DE3427865A1 (de) * 1984-07-27 1986-02-06 Torii & Co., Tokio/Tokyo Amidinoverbindungen, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische mittel
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
US5340833A (en) * 1992-05-01 1994-08-23 Eisai Co., Ltd. Urokinase inhibitors
GB9312761D0 (en) * 1993-06-21 1993-08-04 Wellcome Found Amino acid derivatives
EP0724435B1 (fr) * 1993-10-21 2002-08-14 G.D. Searle & Co. Derives amidino utiles comme inhibiteurs de l'oxyde nitrique-synthase
ZA951617B (en) * 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
US5612353A (en) * 1995-06-07 1997-03-18 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
TW414795B (en) * 1996-07-01 2000-12-11 Yamanouchi Pharma Co Ltd A thiophene derivative and the pharmaceutical composition
DE19632773A1 (de) * 1996-08-14 1998-02-19 Basf Ag Neue Thrombininhibitoren
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
HUP0100082A3 (en) * 1998-01-26 2001-12-28 Abbott Gmbh & Co Kg Thrombin inhibitor, peptide derivatives, pharmaceutical compositions comprising thereof and their use
EP1049673A1 (fr) * 1998-01-26 2000-11-08 Basf Aktiengesellschaft Amidines heterocycliques utilisees comme inhibiteurs de la kallicreine
CA2321025A1 (fr) * 1998-02-09 1999-08-12 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines et guanidines utiles en tant qu'inhibiteurs de protease et plus particulierement en tant qu'inhibiteurs d'urokinase
NZ506985A (en) * 1998-03-31 2003-10-31 Warner Lambert Co Benzoxazinones/benzothiazinones as serine protease inhibitors
KR20010042287A (ko) * 1998-03-31 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세린 프로테아제 억제제로서의 퀴놀론
KR20010042298A (ko) * 1998-03-31 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 인자 Ｘａ 및 트롬빈과 같은 세린 프로테아제억제제로서의 퀴녹살리논

Also Published As

Publication number Publication date
BR9917036A (pt) 2002-07-30
EA200100882A1 (ru) 2002-04-25
NZ513701A (en) 2001-09-28
CN1337961A (zh) 2002-02-27
MXPA01008084A (es) 2004-09-10
ZA200106849B (en) 2002-11-20
CA2362390A1 (fr) 2000-08-17
SK11422001A3 (sk) 2002-04-04
KR20010098982A (ko) 2001-11-08
NO324887B1 (no) 2007-12-27
JP2002536446A (ja) 2002-10-29
AU5671799A (en) 2000-08-29
HUP0201475A2 (hu) 2003-10-28
BG105866A (en) 2002-06-28
NO20013853L (no) 2001-10-09
EP1150979A1 (fr) 2001-11-07
NO20013853D0 (no) 2001-08-07
WO2000047578A1 (fr) 2000-08-17
IL144560A0 (en) 2002-05-23
CZ20012858A3 (cs) 2002-05-15

Similar Documents

Publication Publication Date Title
AU2001251063A1 (en) 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
HUP0300855A3 (en) Peptidmomimetic protease inhibitors, pharmaceutical compositions and their use
ZA200501677B (en) Hydantoin derivatives and their use as TACE inhibitors.
HUP0200347A3 (en) N-cyanomethylamides as protease inhibitors, pharmaceutical compositions containing them and their use
ZA200210411B (en) Novel heteroaryl derivatives and the use thereof as pharmaceuticals.
ZA200210180B (en) Novel heteroaryl derivatives and the use thereof as pharmaceuticals.
PL351767A1 (en) Heteroaryl amidines, methylamidines and guanidines as protease inhibitors
IL159540A0 (en) Heterocyclic compounds as selective bacterial dhfr inhibitors and the uses thereof
MXPA03004848A (es) Derivados de guanidina y amidina como inhibidores del factor xa.
AU2003271223A1 (en) Novel n-hydroxy thiourea, urea and amide compounds and the pharmaceutical compositions comprising the same
EP1235577A4 (fr) Inhibiteurs de protease
AU2424499A (en) Heterocyclic amidines as callicrein protease inhibitors
EP1232155A4 (fr) Inhibiteurs de protease
EP1231921A4 (fr) Inhibiteurs de proteases
EP1229912A4 (fr) Inhibiteurs de protease
EP1229914A4 (fr) Inhibiteurs de protease
EP1229915A4 (fr) Inhibiteurs de protease
EP1173429A4 (fr) Inhibiteurs de protease
HK1043534A1 (zh) 蛋白酶抑制劑
EP1233771A4 (fr) Inhibiteurs de protease
EP1229911A4 (fr) Inhibiteurs de proteases
EP1351930A4 (fr) Inhibiteurs de la protease
AU1039801A (en) Compounds and their use as cysteine protease inhibitors
EP1231923A4 (fr) Inhibiteurs de protease
EP1231922A4 (fr) Inhibiteurs de protease

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)